China Merchants CNI BIOMEDICINE Index Fund-A

399933

165519

159647

161726

The Penghua CSI Chinese Medicine ETF rose by more than 1.8%, influenced by the opinions on the pricing mechanism for pharmaceuticals released by the General Office of the State Council. The opinion aims to regulate the prices of raw and auxiliary materials for medicines and promote the development of high-quality and high-priced Chinese medicinal materials. Institutional analysis suggests that Chinese medicine companies have low valuations and high dividend rates, and will benefit from policy support and market recovery in the future. The CSI Chinese Medicine Index rose by 2.04%, with many Chinese medicine stocks performing strongly. Overall, the state supports the development of traditional Chinese medicine, and the industry is expected to achieve high-quality growth

腾讯新闻 - 财经

800 Health Care

CITIC-Prudential CSI 800 Pharmaceuticals and Biotechnology Index Fund(LOF)-A

Penghua CSI Chinese Medicine ETF

CONBA

Zhongheng Group

BUCHANG PHARMA

ZHONGSHENGYAOYE

YABAO PHARM.CORP

Yunnan Baiyao

ZZPZH

DEEJ

CR Sanjiu

JI LIN AO DONG

GYBYS

BAIYUNSHAN PH

YILING PHARMACEUTICAL

DRTG

TONG REN TANG

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

512290

160635

Guotai CSI Bio-medicine ETF (512290) rose over 1% on April 14, with the focus on innovative drugs going overseas and value realization becoming the market highlight. Xiangcai Securities pointed out that the 2025 global pharmaceutical sales TOP 100 list shows that the industry landscape is undergoing profound changes, with market growth momentum shifting from tumor immunity to chronic diseases such as metabolic disorders, particularly the rise of GLP-1 drugs. Technological iteration has spawned new growth poles, and innovative therapies have become the new engine of growth. This ETF tracks the CSI Bio-medicine Index, reflecting the overall performance of listed companies in the biopharmaceutical sector. Risk warning: Individual stock analysis does not constitute investment advice; investment should be approached with caution

Guotai CSI Bio-medicine ETF

Penghua CSI Health Care Index Fund(LOF)-A

XIANGCAI

Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight

医药生物

159859

399441

Benefiting from the recovery of industry prosperity and favorable policies, more than 50 A-share biomedicine companies are expected to achieve profitability by 2025. According to Wind data, as of January 26, over 90 companies have released performance forecasts, among which 53 companies expect to be profitable, 14 companies expect to double their net profits, 10 companies expect to turn losses into profits, and 14 companies expect to reduce their losses year-on-year

Wallstreetcn

Tianhong CNI BIOMEDICINE ETF

CNI BIOMEDICINE

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025

China Merchants CNI BIOMEDICINE Index Fund-A(161726.SZ)

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

Guotai Bio-medicine ETF (512290) rose over 1%, with the focus on innovative drugs going overseas and value realization becoming the core highlight

With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025